Overview

A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)

Status:
Recruiting

Trial end date:
2023-03-26

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the Mechanism Of Action (MOA) of ruxolitinib cream in vitiligo by assessing the change in biomarkers.

Phase:

Phase 2

Details

Lead Sponsor:

Incyte Corporation